Tissue plasminogen activator: Mechanisms and clinical significance

Read full text Summarise with VIRAT
Authors: Lavudya Naveen, Lalit Kumar Saini, Vijay D. Domple, Sirsat Shraddha D., Deepak Sharma, Subhash Shamrao Raut
Cited by: 0
References: 60

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tissue plasminogen activator (tPA) is a glycoprotein involved in the breakdown of the blood clots. It is a serine protease (EC 3.4.21.68) found on endothelial cells, the cells that line the blood vessels. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. t-PA is synthesized mainly in vascular endothelial cells and is secreted into the plasma continuously and also through the acute release of t-PA. t-PA is a 68 k Da serine protease composed of 530 amino acids. t-PA is used in some cases of diseases that feature blood clots, such as pulmonary embolism, myocardial infarction, and stroke. Therefore, it is necessary to produce thrombolytic medications that are more effective, more focused, affordable, and secure. Although further studies are required to establish downstream processes that will be required to enable medical applications.

Fields of Study & Subjects

Blood Coagulation and Thrombosis Mechanisms Protease and Inhibitor Mechanisms Blood properties and coagulation

Publication details

Journal / source
International Journal of Advanced Biochemistry Research
Volume
10
Issue
3
Pages
788–795
Publication date
1 March 2026
Language
EN